A Phase I Trial to Evaluate Didanosine (ddI) in HIV-Infected Pregnant Women

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

Not specified

Study Completion Date

June 30, 2001

Conditions
HIV InfectionsPregnancy
Interventions
DRUG

Didanosine

Trial Locations (13)

10032

Columbia IMPAACT CRS, New York

Incarnation Children's Ctr., New York

27710

DUMC Ped. CRS, Durham

32209

Univ. of Florida Jacksonville NICHD CRS, Jacksonville

33161

Univ. of Miami Ped. Perinatal HIV/AIDS CRS, Miami

60612

Rush Univ. Med. Ctr. ACTG CRS, Chicago

70112

Tulane Univ. Health Science Ctr., Tulane Univ. Hosp. & Clinic, New Orleans

Tulane/LSU Maternal/Child CRS, New Orleans

90095

UCLA-Los Angeles/Brazil AIDS Consortium (LABAC) CRS, Los Angeles

92093

UCSD Maternal, Child, and Adolescent HIV CRS, San Diego

07103

NJ Med. School CRS, Newark

00936

San Juan City Hosp. PR NICHD CRS, San Juan

Univ. of Puerto Rico Ped. HIV/AIDS Research Program CRS, San Juan

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT00000839 - A Phase I Trial to Evaluate Didanosine (ddI) in HIV-Infected Pregnant Women | Biotech Hunter | Biotech Hunter